Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Infectious Diseases and Clinical Microbiology Specialty Society of Turkey
2022-12-01
|
| Серія: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Предмети: | |
| Онлайн доступ: | https://www.mjima.org/text.php?&id=356 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|